MetaVia Inc. — Director's Dealing 2018

May 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2018-05-01

Reporting Person: Gullans Steven R. Ph.D. (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-01	Employee Stock Option (right to buy)	$5.56	A	150000	Acquired	2028-04-30	Common Stock (150000)	Direct

Footnotes

F1: The option vests in a series of 48 successive equal monthly installments on the last day of each month, commencing on the grant date. The option includes an early exercise provision, subject to the issuer's right of repurchase with respect to any unvested shares of common stock.

F2: The reporting person ceased to be a manager of Excel Venture Fund II, L.P. on May 1, 2018 and will no longer report beneficial ownership of the issuer's securities owned by such entity.